Antibody drug conjugates: A novel targeted approach to cancer therapy

The steady rise in antibody-drug conjugate (ADC) candidates over the past couple of decades reflects the increasing recognition of their potential in targeted cancer therapy. With over 100 ADCs in various stages of clinical trials, and 15 approved treatments, the field is growing at a rapid pace.

This webinar brings together industry experts to explore the successes, current advancements, and future direction on the discovery and development of ADCs, as well as the potential this next generation treatment offers precision oncology.

Hear about:

• Evolution of ADC design and manufacturing techniques
• Observed ADC resistance mechanisms in patients
• Strategies to overcome challenges seen at the clinical stage
• Tailoring ADC therapies for individualized cancer treatment
• Emerging trends and advancements in ADC research

Speakers:

• Gopi Patel, Senior Scientist, Oncology Targeted Discovery - AstraZeneca
• Robert Kupp, PhD, Senior Scientist, Precision Medicine Oncology - AbbVie

For research use only. Not for use in diagnostic procedures.